Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Chemo-free induction-consolidation protocol for Ph+ ALL improved survival

Key clinical point: A front-line chemotherapy-free induction-consolidation protocol with dasatinib and blinatumomab resulted in high survival and molecular response rates in Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).

Major finding: The molecular response rate after blinatumomab cycle two was 60%.

Study details: The phase 2 D-ALBA study included 63 patients with Ph+ ALL.

Disclosures: Dr. Chiaretti reported membership on a board of directors or advisory committee for Pfizer, Incyte, Amgen, and Shire.

Citation:

Chiaretti S et al. ASH 2019, Abstract 740.